Elite Pharmaceuticals (ELTP)

Elite Pharmaceuticals (ELTP) Income Statement


Elite Pharmaceuticals Income Statement

Last quarter (Q1 2024), Elite Pharmaceuticals's total revenue was $9.00M, an increase of 17.30% from the same quarter last year. In Q1, Elite Pharmaceuticals's net income was $1.14M. See Elite Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 23Mar 22Mar 21Mar 20Mar 19
Total Revenue
$ 35.48M$ 34.16M$ 32.26M$ 25.38M$ 17.99M$ 7.57M
Cost of Revenue
$ 18.12M$ 17.56M$ -17.47M$ 13.51M$ 10.02M$ 4.70M
Gross Profit
$ 17.35M$ 16.59M$ 14.80M$ 11.87M$ 7.98M$ 2.87M
Operating Expense
$ 12.80M$ 12.63M$ -9.72M$ 9.76M$ 10.26M$ 12.03M
Operating Income
$ 4.56M$ 3.97M$ 5.07M$ 2.10M$ -2.29M$ -9.16M
Net Non Operating Interest Income Expense
$ -1.69M$ -1.11M$ -191.69K$ -259.08K$ -343.89K$ -347.71K
Other Income Expense
$ -519.02K$ -707.19K$ -2.28M$ 2.30M$ 390.95K$ -448.93K
Pretax Income
$ 4.98M$ 3.99M$ 6.30M$ 4.14M$ -2.24M$ -9.96M
Tax Provision
$ 578.98K$ 424.03K$ -1.74M$ -943.91K$ 2.00K$ 0.00
Earnings From Equity Interest Net Of Tax
----$ 0.00$ 676.02K
Net Income Common Stockholders
$ 4.40M$ 3.56M$ 8.90M$ 5.09M$ -2.24M$ -9.28M
Basic EPS
$ <0.01-$ 0.01$ 0.01$ >-0.01$ -0.01
Diluted EPS
$ -688.32K-$ 0.01$ 0.01$ >-0.01$ -0.01
Basic Average Shares
$ 4.05B$ 1.01B$ 1.01B$ 943.00M$ 832.33M$ 814.17M
Diluted Average Shares
$ 4.05B$ 1.01B$ 1.01B$ 943.00M$ 993.26M$ 816.31M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 30.91M$ 30.19M$ -27.19M$ 23.28M$ 20.28M$ 16.73M
Net Income From Continuing And Discontinued Operation
$ 4.40M$ 3.56M$ 8.90M$ 5.09M$ -2.24M$ -9.28M
Normalized Income
$ 1.75M$ 2.44M-$ 3.41M$ -2.53M$ -8.83M
Interest Expense
$ 242.75K--$ 259.60K$ 355.87K$ 369.17K
$ 6.67M$ 5.09M$ 6.50M$ 4.40M$ -1.88M$ -9.59M
$ 7.98M$ 6.35M$ 7.69M$ 5.93M$ -371.88K$ -8.33M
Currency in USD

Elite Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis